Ovarian Cancer

Study Shows No Increased Risk of Breast Cancer for Non-Carriers in Families with BRCA Gene Mutation

JCO Research Round Up
October 31, 2011

An analysis of more than 3,000 families including women with breast cancer has found that close relatives of women who carry mutations in a BRCA gene - but who themselves do not have such genetic mutations - do not have an increased risk of developing breast cancer compared to relatives of women with breast cancer who do not have such mutations.

Long-Term Treatment with Olaparib May Help Treat Recurrent Ovarian Cancer

ASCO Annual Meeting
May 18, 2011

In a recent study, researchers found that maintenance therapy with olaparib, a type of drug called a PARP inhibitor, increased the amount of time it took for recurrent ovarian cancer (cancer that has come back after treatment) to worsen. Maintenance therapy is ongoing treatment that is given after the standard treatment to help control the growth of cancer.

Cabozantinib Helps Manage Several Advanced Cancers and Shrink Bone Metastases

ASCO Annual Meeting
May 18, 2011

In a recent study, the drug cabozantinib helped manage various advanced cancers, particularly prostate, ovarian, and liver cancers. The drug also helped shrink bone metastases (cancer that has spread to the bone). Cabozantinib is a type of targeted therapy, which means it targets the cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.

Subscribe to RSS - Ovarian Cancer